Susquehanna International Group
RCUS icon

Susquehanna International Group’s Arcus Biosciences RCUS Stock Holding History

Susquehanna International Group’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$324K Buy
+15,000
New +$324K ﹤0.01% 10708
2025
Q4 		– Sell
-59,900
Closed -$815K – 13389
2025
Q3 		$815K Sell
59,900
-17,600
-23% -$183K ﹤0.01% 7827
2025
Q2 		$631K Buy
77,500
+56,500
+269% +$483K ﹤0.01% 8623
2025
Q1 		$165K Sell
21,000
-64,200
-75% -$744K ﹤0.01% 11133
2024
Q4 		$1.27M Sell
85,200
-600
-0.7% -$9.8K ﹤0.01% 6388
2024
Q3 		$1.31M Buy
85,800
+23,800
+38% +$375K ﹤0.01% 6211
2024
Q2 		$944K Sell
62,000
-38,000
-38% -$613K ﹤0.01% 6725
2024
Q1 		$1.89M Sell
100,000
-3,000
-3% -$51.9K ﹤0.01% 5480
2023
Q4 		$1.97M Sell
103,000
-216,600
-68% -$3.46M ﹤0.01% 5385
2023
Q3 		$5.74M Buy
319,600
+2,000
+0.6% +$40.2K ﹤0.01% 3307
2023
Q2 		$6.45M Buy
317,600
+244,500
+334% +$4.66M ﹤0.01% 3120
2023
Q1 		$1.33M Sell
73,100
-106,500
-59% -$2.04M ﹤0.01% 6092
2022
Q4 		$3.71M Buy
179,600
+56,000
+45% +$1.54M ﹤0.01% 3685
2022
Q3 		$3.23M Sell
123,600
-25,300
-17% -$669K ﹤0.01% 3931
2022
Q2 		$3.77M Buy
148,900
+115,800
+350% +$2.84M ﹤0.01% 3671
2022
Q1 		$1.04M Buy
33,100
+4,000
+14% +$134K ﹤0.01% 6995
2021
Q4 		$1.18M Buy
29,100
+7,600
+35% +$295K ﹤0.01% 6865
2021
Q3 		$750K Sell
21,500
-89,800
-81% -$2.79M ﹤0.01% 8315
2021
Q2 		$3.06M Buy
111,300
+18,800
+20% +$537K ﹤0.01% 4975
2021
Q1 		$2.6M Buy
92,500
+47,300
+105% +$1.65M ﹤0.01% 5297
2020
Q4 		$1.17M Sell
45,200
-6,800
-13% -$165K ﹤0.01% 6344
2020
Q3 		$891K Buy
52,000
+25,300
+95% +$565K ﹤0.01% 6392
2020
Q2 		$661K Buy
+26,700
New +$721K ﹤0.01% 6769

Other funds holding RCUS

GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Susquehanna International Group's RCUS Position: Q1 2026 in Review

Susquehanna International Group reduced its Arcus Biosciences (RCUS) stake by 58% in Q1 2026, selling an estimated $4.29M and leaving 143,371 shares worth $3.1M. The position accounts for ﹤0.01% of the portfolio, ranked #5211.

Susquehanna International Group first reported a position in RCUS in Q2 2019 and has held it in 26 quarters since. The position peaked at $8.15M in Q4 2025. 210 funds tracked by Wall St. Rank hold RCUS as of Q1 2026.

  • Susquehanna International Group held 143,371 shares of Arcus Biosciences worth $3.1M as of Q1 2026.
  • Susquehanna International Group sold 198,494 Arcus Biosciences shares in Q1 2026, an estimated $4.29M.
  • Arcus Biosciences made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #5211 holding.
  • Susquehanna International Group first reported a position in Arcus Biosciences in Q2 2019 and has held it in 26 quarters since.
  • Susquehanna International Group's Arcus Biosciences position peaked at $8.15M in Q4 2025.
  • 210 funds tracked by Wall St. Rank held Arcus Biosciences as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.